fosaprepitant

10/18/2023 - "There was a significantly lower cumulative risk of emesis in the fosaprepitant group (HR 0.35 [95% CI 0.19-0.64]; p < 0.001). "
10/18/2023 - "The cumulative incidence of emesis at 5 weeks (competing risk analysis) was 25% (95% CI 14.2-37.4) for the fosaprepitant group compared with 59% (95% CI 43.9-71.0) for the control group. "
01/01/2023 - "In this pilot randomized clinical trial, there was no statistically significant difference in the complete response primary end point, but patients receiving weekly fosaprepitant were less likely to experience emesis compared with those who received fosaprepitant every 3 weeks, especially in the subgroup with a mean brainstem dose of 36 Gy or more. "
09/01/2020 - "Fosaprepitant could also reduce the incidence of vomiting significantly both 0-24h and 0-48hours postoperatively (OR = 0.07; 95% CI 0.02-0.24; p < 0.001 and OR = 0.07; 95% CI 0.02-0.23; p < 0.001). "
04/01/2016 - "There was a significantly lower cumulative risk of emesis in the fosaprepitant group compared with the placebo group (subhazard ratio 0·58 [95% CI 0·39-0·87]; p=0·008). "

11/20/2023 - "She was given a one-time dose of fosaprepitant 150 mg intravenously (IV) with marked improvement of her nausea. "
11/20/2023 - "Use of Fosaprepitant for Management of Suspected Antimicrobial-Associated Nausea: A Case Report."
01/01/2016 - "In the overall phase, the proportion of subjects with no vomiting (82.7% versus 72.9%; P < 0.001) and no significant nausea (83.2% versus 77.9%; P = 0.030) was also significantly improved with the fosaprepitant regimen. "
01/01/2023 - "The proportion of patients with sustained no emesis (38% vs 14%; P = .003) or no significant nausea (92% vs 72%; P = .002) was significantly higher in the group that received fosaprepitant weekly vs those who received fosaprepitant every 3 weeks. "
11/01/2017 - "Fosaprepitant provided effective and well-tolerated control of nausea and vomiting associated with HEC in Chinese patients."

09/25/2020 - "This post hoc analysis indicated that a single-day fosaprepitant regimen was effective in preventing CINV in patients receiving MEC, regardless of cancer type. "
09/25/2020 - "The fosaprepitant regimen was well tolerated in all cancer subgroups. "
09/25/2020 - "CR rates in the delayed phase favored the fosaprepitant regimen over the control regimen across the GI/colorectal, lung, breast, and gynecologic cancer subgroups (range, 6.2-22%); similar findings were observed for CR in the overall phase. "
09/01/2020 - "This evaluation is a retrospective review of electronic health records of adult patients who received their first dose of fosaprepitant for CINV prophylaxis beginning January 1, 2017 through June 30, 2017 at the University of Colorado Cancer Center outpatient infusion center. "
07/01/2019 - "Medical records of patients with cancer receiving intravenous fosaprepitant through a peripheral intravenous line were reviewed. "

10/01/2023 - "Fosaprepitant for postoperative nausea and vomiting in patients undergoing laparoscopic gastrointestinal surgery: a randomised trial."
10/01/2023 - "The incidence of PONV during the first 24 postoperative hours was lower in the fosaprepitant group (32.4% vs 48.7%; adjusted risk difference -16.9% [95% confidence interval: -22.4 to -11.4%]; adjusted risk ratio 0.65 [95% CI: 0.57 to 0.76]; P<0.001). "
06/01/2023 - "Total PONV medication cost decreased with the replacement of standard of care regimen for fosaprepitant, from 46.47±20.54 United States Dollars in the no-Fosaprepitant group to 25.69±14.84 United States Dollars in the Fosaprepitant group. "
03/01/2015 - "We present a case that illustrates the use of fosaprepitant for the treatment of refractory postoperative nausea and vomiting. "
03/01/2015 - "Fosaprepitant for the Treatment of Refractory Postoperative Nausea and Vomiting."

01/01/2021 - "Fosaprepitant repurposing shows promise for the treatment of ocular pain."
01/01/2021 - "Similarly, a single dose of 10 or 50 mg/mL fosaprepitant applied topically to WT mice reduced ocular pain as compared to vehicle (P < 0.001). "
01/01/2016 - "The dose-limiting side effect of fosaprepitant is an infusion-related reaction, ranging from pain at the infusion site to thrombophlebitis. "
12/01/2017 - "Fosaprepitant is a potentially novel adjuvant therapy for the treatment of refractory inflammatory pain syndromes in palliative care."
12/01/2017 - "Given the underlying inflammatory nature of her pain syndrome, and the role of substance P (SP) in pain transmission and modulation, we decided to use fosaprepitant, an SP and neurokinin-1 (NK1) receptor antagonist. "